Journal: BMC Genetics

Article Title: Polymorphic variability in the 3' untranslated region (UTR) of IL12B is associated with susceptibility to severe anaemia in Kenyan children with acute Plasmodium falciparum malaria

doi: 10.1186/1471-2156-12-69

Figure Lengend Snippet: Distribution of IL12B 3' UTR genotypes in children with P. falciparum malaria

Article Snippet: Genomic DNA was amplified using the Genomiphi DNA amplification kit (GE Healthcare, Life Sciences, Amersham), and the rs3212227 was genotyped using a Taqman ® 5' allelic discrimination Assay-By-Design method according to manufacturer's instructions (Assay ID: C_2084293_10; Applied Biosystems).

Techniques:

Journal: Molecular Medicine Reports

Article Title: Mycoleptodonoides aitchisonii suppresses asthma via Th2 and Th1 cell regulation in an ovalbumin-induced asthma mouse model

doi: 10.3892/mmr.2017.7901

Figure Lengend Snippet: M. atichisonii significantly inhibited the expression of Th2-related cytokines in a dose-dependent manner. (A) M. atichisonii suppressed the expression of TNF-α similarly to dexamethasone treatment. (B) M. atichisonii downregulated the expression of IL-4. (C) M. atichisonii significantly inhibited the expression of IL-5, similar to treatment with dexamethasone. (D) M. atichisonii dramatically inhibited the expression of IL-6 more than treatment with dexamethasone. (E) The expression of IL-13 dramatically inhibited the expression of IL-6 more than treatment with dexamethasone. (F) Quantification of expression. Each bar represents the mean ± standard deviation (n=6). a, Con; b, OVA; c, DEX; d, 10 mg/kg/day M. atichisonii ; e, 100 mg/kg/day M. atichisonii ; f, 1,000 mg/kg/day M. atichisonii . *P<0.05 vs. control; **P<0.001 vs. control; $ P<0.05 vs. OVA-induced asthma, $$ P<0.001 vs. OVA-induced asthma; # P<0.05 vs. DEX treatment, ## P<0.01 vs. DEX treatment. Th, T helper; TNF-α, tumor necrosis factor-α; IL, interleukin; Br, bronchiole; V, vessel; Con, control; OVA, ovalbumin; DEX, dexamethasone.

Article Snippet: The slides were incubated with normal serum to block non-specific binding and then incubated overnight at 4°C with the following primary antibodies (diluted 1:100 to 1:200): Rabbit anti-mouse CD3 polyclonal (cat no. ab5690; 1:100; Abcam, Cambridge, MA, USA), rat anti-mouse CD4 monoclonal (cat no. 14-9766; 1:200; eBioscience, Inc., San Diego, CA, USA), rat anti-mouse CD8 monoclonal (cat no. sc-18913; 1:100; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), rabbit anti-mouse CD19 polyclonal (cat no. 250585; 1:100; Abbiotec, San Diego, CA, USA), rat anti-mouse MHC class II monoclonal (cat no. sc-59318; 1:100; Santa Cruz Biotechnology, Inc.), rabbit anti-mouse Tbx21/T-bet polyclonal (cat no. bs-3599R; 1:100; BIOSS, Beijing, China), goat anti-mouse GATA-3 (cat no. TA305795; 1:100; OriGene Technologies, Inc., Rockville, MD, USA), rat anti-mouse IFN-γ monoclonal (cat no. sc-74104; 1:100), goat anti-mouse IL-12p35 polyclonal (cat no. sc-9350; 1:100), rat anti-mouse IL-12p40 monoclonal (cat no. sc-57258; 1:100) (all from Santa Cruz Biotechnology, Inc.), rabbit anti-mouse TNF-α polyclonal (cat no. 3053R-100; 1:200; BioVision Milpitas, CA, USA), rat anti-mouse IL-4 monoclonal (cat no. sc-73318; 1:100), rabbit anti-mouse IL-5 polyclonal (cat no. sc-7887; 1:100), goat anti-mouse IL-6 polyclonal (cat no. sc-1265; 1:100), and goat anti-mouse IL-13 polyclonal (cat no. sc-1776; 1:100) (all from Santa Cruz Biotechnology, Inc.).

Techniques: Expressing, Standard Deviation